What are the complement levels in post-streptococcal (post-strep) glomerulonephritis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Complement Levels in Post-Streptococcal Glomerulonephritis

Complement levels, specifically C3, are typically decreased during the acute phase of post-streptococcal glomerulonephritis (PSGN) 1.

  • The degree of C3 depression can vary, but it is often more pronounced in patients with severe disease.
  • Serial measurements of C3 levels can be useful in monitoring disease activity and response to treatment.
  • Levels usually return to normal within 8-12 weeks 1.
  • Persistently low C3 in serum beyond week 12 may be an indication for kidney biopsy to exclude complement C3 glomerulonephritis (C3GN) 1.
  • No specific medication, such as corticosteroids or immunosuppressants, is typically required for complement level management in PSGN.
  • C4 levels may also be assessed, but the primary focus is on C3 levels in the context of PSGN 1.

From the Research

Complement Levels in Post-Streptococcal Glomerulonephritis

  • Complement levels are decreased in patients with post-streptococcal glomerulonephritis (PSGN), with low serum C3, properdin, and C5 levels indicating aggressive complement activation 2, 3, 4.
  • The classical complement pathway is frequently activated in patients with PSGN, with elevated C4d/C4 ratios indicating C4 activation 5.
  • C3 and C5 levels are decreased in PSGN, with C3 levels being decreased in more than 90% of cases 4.
  • C4 levels are typically normal or only slightly decreased in PSGN, with the early return to normal of fourth component concentrations being a favourable prognostic sign 2, 5.
  • Other complement components, such as C6 and C8, may also be decreased in some patients with PSGN, particularly those with low C3 levels 5.

Patterns of Complement Activation

  • Complement activation in PSGN is thought to occur through the alternative pathway, with C3 splitting activity present before the clinical onset of nephritis 3.
  • The activation of the classical pathway also plays a role in PSGN, with C4 activation occurring in some patients 5.
  • The pattern of complement activation in PSGN is distinct from that seen in other types of glomerulonephritis, such as systemic lupus erythematosus 2.

Clinical Implications

  • Decreased complement levels, particularly C3, are a hallmark of PSGN and can be used to diagnose and monitor the disease 4, 6.
  • Measuring C3 and C4 levels may also be helpful in evaluating other causes of acute nephritis 4.
  • The management of PSGN is mainly supportive, with fluid restriction, anti-hypertensives, diuretics, and renal replacement therapy as needed 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.